Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter

Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter

Objectives:. To determine whether Seraph-100 (Exthera Medical Corporation, Martinez, CA) treatment provides clinical benefit for severe coronavirus disease 2019 cases that require mechanical ventilation and vasopressor support. Data Sources:. The first two patients in the United States treated with...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephen W. Olson, MD, James D. Oliver, MD, PhD, Jacob Collen, MD, Jessica Bunin, MD, Todd D. Gleeson, MD, Brian E. Foster, DO, Mark P. Simmons, PhD, Hua W. Chen, PhD, Jennifer B. Ficke, MD, Tara E. Brown, MD, Mark T. Nau, MD, Brennan R. Cebula, MD, Jan Kielstein, MD, Kevin K. Chung, MD
Format: Article
Language:English
Published: Wolters Kluwer 2020-08-01
Series:Critical Care Explorations
Online Access:http://journals.lww.com/10.1097/CCE.0000000000000180
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://journals.lww.com/10.1097/CCE.0000000000000180

Similar Items